Session 7 Discussion

European Meeting on HIV & Hepatitis 2016

Improving PI drug resistance scores | Jens Verheyen, MD, PhD

European Meeting on HIV & Hepatitis 2016

PI remain important options for first line | Linos Vandekerckhove, MD, PhD

European Meeting on HIV & Hepatitis 2016

Session 5 Discussion

European Meeting on HIV & Hepatitis 2016

Maintenance Therapy - What is the scientific/ virological rational | Charles Boucher, MD, PhD

European Meeting on HIV & Hepatitis 2016

HIV attachment Inhibitors - Educational lecture in collaboration with ESAR | Thomas Klimkait, MD

European Meeting on HIV & Hepatitis 2016

Session 4 Discussion

European Meeting on HIV & Hepatitis 2016

Community perspective | Rebekah Webb

European Meeting on HIV & Hepatitis 2016

Roadblocks to implementation | Pep Coll, MD

European Meeting on HIV & Hepatitis 2016

HIV in Europe 2020 – what will it look like? | Carlo Federico Perno, MD, PhD

European Meeting on HIV & Hepatitis 2016

What challenges remain in viral hepatitis | Jürgen Rockstroh, MD

International Workshop on HIV & Hepatitis Co-infection 2017

HCV elimination program in Georgia: Successes and challenges | Nikoloz Chkhartishvili, MD, MS, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Antifibrotics and fatty liver drugs in the pipeline | Sanjay Bhagani, MD

International Workshop on HIV & Hepatitis Co-infection 2017

NASH and NAFLD in HIV: same or different? | Mariana Machado, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Non liver and survival benefits of SVR in HCV | Marion Peters, MD

International Workshop on HIV & Hepatitis Co-infection 2017

The use of HIV+ or HCV+ organs in transplantation | Stefano Fagiuoli, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Are there any special populations in treatment of HCV left? | Douglas Dieterich, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Pharmacologist's perspective | David Back, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Virologist's perspective | Charles Boucher, MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Special considerations before / during / after DAA therapy | Kosh Agarwal, MD

International Workshop on HIV & Hepatitis Co-infection 2017

HBV cure: what is coming in 5 – 10 years? | Patrick Kennedy, MD

International Workshop on HIV & Hepatitis Co-infection 2017

EASL highlights 2017 | Jürgen Rockstroh, MD

International Workshop on HIV & Hepatitis Co-infection 2017

Management of end-stage liver disease in HIV patients | Ana Morbey, MD

International Workshop on HIV & Hepatitis Co-infection 2017

News on hepatitis delta and HIV infections | Vincent Soriano, MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017